Skip to main content
AprilBio Co.,Ltd. logo

AprilBio Co.,Ltd. — Investor Relations & Filings

Ticker · 397030 ISIN · KR7397030008 KO Professional, scientific and technical activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2024-04-29 Legal Proceedings Report
Country KR South Korea
Listing KO 397030

About AprilBio Co.,Ltd.

http://www.aprilbio.com/en/

AprilBio is a biotechnology company that develops innovative biologic drugs, including therapeutic antibodies and recombinant proteins. The company's core is its proprietary SAFA (anti-Serum Albumin Fab-Associated) platform technology, which utilizes an albumin-binding antibody fragment to create long-acting therapeutics. This platform is designed to enhance the efficacy, safety, and plasma half-life of drug candidates while minimizing adverse effects. AprilBio's research and development pipeline focuses on addressing unmet medical needs in therapeutic areas such as autoimmune diseases, oncology, and other inflammatory and rare diseases. The company advances new drug candidates through early clinical development stages for potential technology transfer.

Recent filings

Filing Released Lang Actions
불성실공시법인지정 (공시불이행)
Legal Proceedings Report Classification · 100% confidence The document is a formal notice from a regulatory body (KOSDAQ) regarding the designation of the company as an 'unfaithful disclosure corporation' due to a delay in reporting clinical trial results. This is a regulatory announcement concerning compliance and legal/regulatory status, which fits the 'Regulatory Filings' (RNS) category as it does not fall into specific categories like legal proceedings (lawsuits) or management changes.
2024-04-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings (specifically stock options) for an executive (Han Jae-gyu) of AprilBio. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2024-04-22 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow) scheduled for April 2024. It provides details such as date, location, and purpose, but does not contain the actual presentation materials. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Regulatory Filing (RNS) when it does not fit into more specific categories like RPA (which is typically for report publication). Since this is a standard regulatory disclosure of an IR event, RNS is the appropriate classification.
2024-04-11 Korean
불성실공시법인지정예고 (공시불이행)
Regulatory Filings Classification · 100% confidence The document is a formal notice from the Korea Exchange regarding the 'designation of an unfaithful disclosure corporation' (불성실공시법인지정예고) for AprilBio. It details a regulatory action concerning a delayed disclosure of clinical trial results. Since this relates to regulatory compliance and legal/disciplinary proceedings regarding disclosure obligations, it falls under the 'Regulatory Filings' category as it does not fit into specific financial reporting or corporate action categories.
2024-04-04 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (AGM) for the company 'AprilBio'. It details the voting outcomes for various agenda items such as financial statement approval, director appointments, and remuneration limits. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements'.
2024-03-20 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and legal basis. This type of disclosure regarding capital structure changes and equity-based compensation is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (insider trading) or SHA (share issuance/capital change) which typically refer to broader capital structure changes or direct trading.
2024-03-20 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.